Hematologic and organ toxicity in patients with NHL treated with 131I-labeled ch81C6 mAb
. | Patient no. . | . | . | . | . | . | . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Toxicity . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | 8 . | 9 . | ||||||||
| Administered dose, MBq | 1480 | 1480 | 1480 | 1110 | 1110 | 1110 | 1110 | 1110 | 1110 | ||||||||
| Administered dose, MBq/kg | 14.6 | 24.4 | 18.7 | 14.9 | 18.7 | 15.9 | 12.9 | 13.7 | 11.5 | ||||||||
| White cell range, × 109/L (d for recovery to ≤ grade 1) | 5.8-12.2 (0) | 4.7-0.5 (20) | 4.3-0.4 (12) | 4.7-0.5 (21) | 4.1-2.0 (41) | 9-0.9 (41) | 3.2-1.0 (49) | 6.6-0.1 (14) | 5.8-1.1 (49) | ||||||||
| No. d ANC was below 0.5 × 109/L | 0 | 20 | 4 | 7 | 0 | 21 | 0 | 13 | 0 | ||||||||
| Platelet decrease, × 109/L (d for recovery to ≤ grade 1) | 234-12 (35) | 216-10 (20) | 154-5 (30) | 372-7 (28) | 164-47 (22) | 186-6 (70) | 113-8 (28) | 333-8 (33) | 190-8 (40) | ||||||||
| No. d platelets were below 25 × 109/L | 27 | 13 | 18 | 12 | 0 | 40 | 13 | 14 | 28 | ||||||||
| Hemoglobin decrease, g L-1 (no. units red cell transfusions delivered)* | 110-67 (2) | 100-80 (2) | 107-90 (0) | 107-93 (0) | 103-93 (0) | 137-63 (4) | 120-87 (0) | 107-80 (4) | 123-90 (0) | ||||||||
| Required stem cell re-infusion | No | Yes | Yes | No | No | Yes | No | Yes | No | ||||||||
| Pulmonary toxicity | None | None | None | None | None | None | None | None | None | ||||||||
| Hepatic toxicity | None | None | None | None | None | None | None | None | None | ||||||||
| Neural toxicity | None | None | None | None | None | None | None | None | None | ||||||||
| Renal toxicity | None | None | None | None | None | None | None | None | None | ||||||||
| Cardiac toxicity | None | None | None | None | None | None | None | None | None | ||||||||
. | Patient no. . | . | . | . | . | . | . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Toxicity . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | 8 . | 9 . | ||||||||
| Administered dose, MBq | 1480 | 1480 | 1480 | 1110 | 1110 | 1110 | 1110 | 1110 | 1110 | ||||||||
| Administered dose, MBq/kg | 14.6 | 24.4 | 18.7 | 14.9 | 18.7 | 15.9 | 12.9 | 13.7 | 11.5 | ||||||||
| White cell range, × 109/L (d for recovery to ≤ grade 1) | 5.8-12.2 (0) | 4.7-0.5 (20) | 4.3-0.4 (12) | 4.7-0.5 (21) | 4.1-2.0 (41) | 9-0.9 (41) | 3.2-1.0 (49) | 6.6-0.1 (14) | 5.8-1.1 (49) | ||||||||
| No. d ANC was below 0.5 × 109/L | 0 | 20 | 4 | 7 | 0 | 21 | 0 | 13 | 0 | ||||||||
| Platelet decrease, × 109/L (d for recovery to ≤ grade 1) | 234-12 (35) | 216-10 (20) | 154-5 (30) | 372-7 (28) | 164-47 (22) | 186-6 (70) | 113-8 (28) | 333-8 (33) | 190-8 (40) | ||||||||
| No. d platelets were below 25 × 109/L | 27 | 13 | 18 | 12 | 0 | 40 | 13 | 14 | 28 | ||||||||
| Hemoglobin decrease, g L-1 (no. units red cell transfusions delivered)* | 110-67 (2) | 100-80 (2) | 107-90 (0) | 107-93 (0) | 103-93 (0) | 137-63 (4) | 120-87 (0) | 107-80 (4) | 123-90 (0) | ||||||||
| Required stem cell re-infusion | No | Yes | Yes | No | No | Yes | No | Yes | No | ||||||||
| Pulmonary toxicity | None | None | None | None | None | None | None | None | None | ||||||||
| Hepatic toxicity | None | None | None | None | None | None | None | None | None | ||||||||
| Neural toxicity | None | None | None | None | None | None | None | None | None | ||||||||
| Renal toxicity | None | None | None | None | None | None | None | None | None | ||||||||
| Cardiac toxicity | None | None | None | None | None | None | None | None | None | ||||||||
National Cancer Institute toxicity grading scale for hematologic parameters: white cell toxicity grade 2, 2-3 × 109/L; grade 3, 1-2 × 109/L; grade 4, < 1 × 109/L (growth factor support was not used in this trial). Platelet toxicity grade 2, 50-75 × 109/L; grade 3, 25-50 × 109/L; grade 4, < 25 × 109/L. Hemogl obin toxicity grade 2, 80-100 g/L; grade 3, 65-80 g/L; grade 4, < 65 g/L.
Transfusions delivered with packed red blood cells.